Neos Therapeutics to Present at Stifel 2016 Healthcare Conference
November 08 2016 - 8:00AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing and commercializing innovative
extended-release (XR) products for the treatment of
attention-deficit/hyperactivity disorder (ADHD), today announced
that Vipin Garg, Ph.D., president and chief executive officer, will
present a company overview at the upcoming Stifel 2016 Healthcare
Conference on Tuesday, November 15, 2016 at 3:45 p.m. ET in New
York, NY.
A live webcast of the presentation will be available on the
Investor Relations page of the company’s website at
http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused
on developing, manufacturing and commercializing products utilizing
its proprietary modified‐release drug delivery technology
platforms. Adzenys XR-ODT, indicated for the treatment of ADHD, is
the first approved product using the Company’s XR-ODT technology
platform. Neos, which is initially focusing on the treatment
of ADHD, has two other branded product candidates that are XR
medications in ODT or liquid suspension dosage forms. In
addition, Neos manufactures and markets its generic
equivalent of the branded product Tussionex®1, an XR liquid
suspension of hydrocodone and chlorpheniramine indicated for the
relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of
Companies.
Contact:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024